Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
52.8M
-
Shares change
-
-1.33M
-
Total reported value, excl. options
-
$58.1M
-
Value change
-
-$1.61M
-
Put/Call ratio
-
0.1
-
Number of buys
-
41
-
Number of sells
-
-57
-
Price
-
$1.10
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q2 2024
119 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q2 2024.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.8M shares
of 108M outstanding shares and own 48.79% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (13M shares), VANGUARD GROUP INC (4.69M shares), MILLENNIUM MANAGEMENT LLC (3.34M shares), D. E. Shaw & Co., Inc. (3.32M shares), Rock Springs Capital Management LP (2.75M shares), BlackRock Inc. (2.03M shares), Stonepine Capital Management, LLC (1.93M shares), ACADIAN ASSET MANAGEMENT LLC (1.91M shares), Trium Capital LLP (1.89M shares), and TWO SIGMA ADVISERS, LP (1.44M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.